“SOLUBLE ST2 AND CD163 AS POTENTIALBIOMARKERS TO DIFFERENTIATE PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FROM MACROPHAGE ACTIVATION SYNDROME”, Mediterr J Hematol Infect Dis, vol. 11, no. 1, p. e2019008, Jan. 2019, doi: 10.4084/mjhid.2019.008.